Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Giuseppe Visani

Showing results (1-10 of 103) with videos related to

Pageof 11
Sort By:
Expert Opinion on Pharmacotherapy|October 25, 2013
Resistant chronic myeloid leukemia beyond tyrosine-kinase inhibitor therapy: which role for omacetaxine?Giuseppe Visani, Alessandro Isidori
Expert Review of Anticancer Therapy|March 12, 2009
Nonpegylated liposomal doxorubicin in the treatment of B-cell non-Hodgkin's lymphoma: where we standGiuseppe Visani, Alessandro Isidori
Nanomedicine (London, England)|November 22, 2014
Nanomedicine strategies for hematological malignancies: what is next?Giuseppe Visani, Federica Loscocco, Alessandro Isidori
Leukemia & Lymphoma|June 1, 2016
Novel regimens prior to autologous stem cell transplantation for the management of adults with relapsed/refractory non-Hodgkin lymphoma and Hodgkin lymphoma: alternatives to BEAM conditioningAlessandro Isidori, Anna Christofides, Giuseppe Visani
Current Opinion in Oncology|October 11, 2023
Fms -like tyrosine kinase 3 positive acute myeloid leukemiaAlessandro Isidori, Giuseppe Visani, Felicetto Ferrara
Psychological Reports|October 7, 2010
Self-awareness training associated with personality traits and sex: a pilot studyGiuseppe Visani, Piero Venturi, Alessandro Isidori, et al.
Leukemia & Lymphoma|September 17, 2004
Low dose Ara-C for myelodysplastic syndromes: is it still a current therapy?Giuseppe Visani, Michele Malagola, Pier Paolo Piccaluga, et al.
Expert Review of Hematology|May 25, 2018
Genetic profiling in acute myeloid leukemia: a path to predicting treatment outcomeGiuseppe Visani, Federica Loscocco, Alessandro Isidori, et al.
Cancers|November 15, 2018
Novel Agents for Acute Myeloid LeukemiaMario Luppi, Francesco Fabbiano, Giuseppe Visani, et al.
Frontiers in Oncology|October 16, 2019
BCR-ABL Independent Mechanisms of Resistance in Chronic Myeloid LeukemiaFederica Loscocco, Giuseppe Visani, Sara Galimberti, et al.
Pageof 11

Showing results (1-10 of 103) with videos related to

Sort By:
Pageof 11
Expert Opinion on Pharmacotherapy|October 25, 2013
Resistant chronic myeloid leukemia beyond tyrosine-kinase inhibitor therapy: which role for omacetaxine?Giuseppe Visani, Alessandro Isidori
Expert Review of Anticancer Therapy|March 12, 2009
Nonpegylated liposomal doxorubicin in the treatment of B-cell non-Hodgkin's lymphoma: where we standGiuseppe Visani, Alessandro Isidori
Nanomedicine (London, England)|November 22, 2014
Nanomedicine strategies for hematological malignancies: what is next?Giuseppe Visani, Federica Loscocco, Alessandro Isidori
Leukemia & Lymphoma|June 1, 2016
Novel regimens prior to autologous stem cell transplantation for the management of adults with relapsed/refractory non-Hodgkin lymphoma and Hodgkin lymphoma: alternatives to BEAM conditioningAlessandro Isidori, Anna Christofides, Giuseppe Visani
Current Opinion in Oncology|October 11, 2023
Fms -like tyrosine kinase 3 positive acute myeloid leukemiaAlessandro Isidori, Giuseppe Visani, Felicetto Ferrara
Psychological Reports|October 7, 2010
Self-awareness training associated with personality traits and sex: a pilot studyGiuseppe Visani, Piero Venturi, Alessandro Isidori, et al.
Leukemia & Lymphoma|September 17, 2004
Low dose Ara-C for myelodysplastic syndromes: is it still a current therapy?Giuseppe Visani, Michele Malagola, Pier Paolo Piccaluga, et al.
Expert Review of Hematology|May 25, 2018
Genetic profiling in acute myeloid leukemia: a path to predicting treatment outcomeGiuseppe Visani, Federica Loscocco, Alessandro Isidori, et al.
Cancers|November 15, 2018
Novel Agents for Acute Myeloid LeukemiaMario Luppi, Francesco Fabbiano, Giuseppe Visani, et al.
Frontiers in Oncology|October 16, 2019
BCR-ABL Independent Mechanisms of Resistance in Chronic Myeloid LeukemiaFederica Loscocco, Giuseppe Visani, Sara Galimberti, et al.
Pageof 11